Study over 2,200 patients confirms high accuracy of PrenaTest® for fetal trisomies
Bonn/Konstanz, November 14, 2016 – LifeCodexx AG today announced final top line results from a prospective Post-Market Clinical Follow-up study (PMCF) for the PrenaTest®, Europe’s first non-invasive prenatal test (NIPT).
Under the direction of Prof. Dr. med. Annegret Geipel of the University Hospital Bonn, the study compared results of the PrenaTest® for the detection of fetal trisomies 13, 18 and 21 with results from invasive testing and birth outcomes. More than 2,200 women with singleton pregnancies from Germany were included in the blinded multicenter study, which was conducted in cooperation with more than 400 physicians between February 2013 and July 2016. Final results of the Post-Market Clinical Follow-up study were presented by the University Hospital Bonn at the congress of the German Society for Gynecology and Obstetrics in October 2016.
To read more please click http://lifecodexx.com/en/prospective-clinical-follow-up-study-with-over-2200-patients-confirms-high-test-accuracy-of-prenatest-for-fetal-trisomies/